15 completed, 4 recruiting, 2 withdrawn, 1 not yet recruiting. 25 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 15, Recruiting 4, Withdrawn 2, Not yet recruiting 1, Suspended 1, Terminated 1, Unknown 1 |
| Phase 2 | 11 | Completed 6, Recruiting 3, Suspended 1, Unknown 1 |
Follow NAC: new trials by email Literature Review of NAC trials Research Report on NAC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis Placebo, NAC - SBP - Spontaneous Bacterial Peritonitis | Phase 1 / Phase 2 | Recruiting | Tanta University | 60 | 2026-10-25 | 2026-10-30 |
| Tolerability of Enteral NAC in Infants N-Acetylcysteine - Biliary Atresia | Phase 1 | Not yet recruiting | Sanjiv Harpavat | 12 | 2026-10-01 | 2026-03-04 |
| Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT N-Acetyl-Cysteine, Placebo - Ovarian Cancer, Cognitive Impairment | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 102 | 2026-05-21 | 2026-07-17 |
| Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) Acetylcysteine, EH301, Riluzole - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Biogipuzkoa Health Research Institute | 90 | 2025-11-25 | 2026-02-17 |
| Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels N-Acetylcysteine - Mitochondrial Disease | Phase 1 | Recruiting | Michio Hirano, MD | 18 | 2023-07-06 | 2026-01-23 |
| Effect of Acetaminophen and N-Acetylcysteine on Liver Metabolism on Homocystinuria Acetaminophen, N-acetylcysteine - CBS Deficiency | Phase 1 / Phase 2 | Suspended | Hospital de Clinicas de Porto Alegre | 10 | 2022-02-11 | 2021-06-30 |
| Efficacy and Safety of Rifaximin With NAC in IBS-D Rifaximin, N-acetylcysteine, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 1 / Phase 2 | Completed | Cedars-Sinai Medical Center | 45 | 2020-11-13 | 2023-03-28 |
| Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19 Famotidine, N-Acetyl cysteine - Covid19 | Phase 1 | Terminated | Prisma Health-Upstate | 2 | 2020-10-20 | 2022-02-18 |
| Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity. N-Acetyl Cysteine - Ototoxic Hearing Loss | Phase 1 / Phase 2 | Unknown | Sunnybrook Health Sciences Centre | 80 | 2020-02-26 | 2023-09-06 |
| Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Hyperpolarized Pyruvate (13C) Injection, Coil Testing, NAC - Breast Cancer | Phase 1 | Withdrawn | Sunnybrook Health Sciences Centre | 2017-11-21 | 2023-03-30 | |
| A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes N-acetyl cysteine, Placebo - Type 1 Diabetes, Hypoglycemia Unawareness | Phase 1 / Phase 2 | Completed | University of Minnesota | 22 | 2015-02-01 | 2020-01-31 |
| Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC HPN-07, NAC, Placebo - Hearing Loss, Sensorineural Hearing Loss | Phase 1 | Completed | Otologic Pharmaceutics, Inc. | 32 | 2014-10-01 | 2015-05-01 |
| Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose N-acetylcysteine - Drug-Induced Acute Liver Injury | Phase 1 | Completed | University of Aarhus | 16 | 2014-09-08 | 2018-09-24 |
| MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) MK-8237, Placebo, NAC - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 26 | 2013-11-27 | 2019-03-15 |
| N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults PharmaNAC (N-acetylcysteine), Matching placebo - HIV, Endothelial Dysfunction | Phase 1 / Phase 2 | Completed | Indiana University | 24 | 2013-10-01 | 2016-02-08 |
| N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia N-acetylcysteine (NAC), Inactive placebo capsule - Schizophrenia | Phase 1 | Completed | VA Greater Los Angeles Healthcare System | 26 | 2013-06-01 | 2015-06-04 |
| N-Acetylcysteine for Neuroprotection in Parkinson's Disease N-acetylcysteine, Placebo - Parkinson Disease | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 50 | 2012-01-01 | 2018-08-28 |
| Hypertrophic Regression With N-Acetylcysteine in HCM N-acetylcysteine, Placebo - Hypertrophic Cardiomyopathy | Phase 1 | Completed | The University of Texas Health Science Center, Houston | 42 | 2012-01-01 | 2021-11-02 |
| Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease N-acetylcysteine - Parkinson's Disease, Gaucher's Disease | Phase 1 | Completed | University of Minnesota | 9 | 2011-07-01 | 2019-11-01 |
| Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly N-acetylcysteine, Losartan, Placebo losartan - Aging | Phase 1 / Phase 2 | Completed | The University of Texas Medical Branch, Galveston | 6 | 2011-07-01 | 2018-05-08 |
Showing 20 of 25. Sign in to see all of them.
Cognitive Dysfunction (2) · Deafness (2) · Diabetes Mellitus (2) · Hearing Loss (2) · Hearing Loss, Sensorineural (2) · Ovarian Neoplasms (2) · Parkinson Disease (2) · Amyotrophic Lateral Sclerosis (1) · Biliary Atresia (1) · Breast Neoplasms (1) · COVID-19 (1) · Carcinoma, Ovarian Epithelial (1) · Cardiomyopathy, Hypertrophic (1) · Cardiovascular Diseases (1) · Chemical and Drug Induced Liver Injury (1)
Sunnybrook Health Sciences Centre (2) · University of Minnesota (2) · Altheus Therapeutics, Inc. (1) · Baylor College of Medicine (1) · Biogipuzkoa Health Research Institute (1) · Cedars-Sinai Medical Center (1) · Charles Drew University of Medicine and Science (1) · Hospital de Clinicas de Porto Alegre (1) · Indiana University (1) · Merck Sharp & Dohme LLC (1) · Michio Hirano, MD (1) · OHSU Knight Cancer Institute (1) · Otologic Pharmaceutics, Inc. (1) · Prisma Health-Upstate (1) · Sanjiv Harpavat (1)
United States (17) · Canada (2) · Brazil (1) · Egypt (1) · Spain (1)
Ali J. Marian, MD (1) · Astrid M Horstman, PhD (1) · Charles Cunningham, PhD (1) · Daniela Bota, MD, PhD (1) · Dikoma C. Shungu, Ph.D. (1) · Edward A Neuwelt, MD (1) · Elizabeth Seaquist, MD (1) · Handan Gunduz-Bruce, M.D. (1) · Ida VD Schwartz, PhD (1) · John J O'Connell, M.D. (1) · Mark Pimentel, MD (1) · Melinda Sheffield-Moore, PhD (1) · Michael C Davis, M.D., Ph.D. (1)
PMID 23860343, PMID 28911971, PMID 29540445, PMID 35288511, PMID 36114762
R21AG041509 (1), R21DA024756 (1), U54NS065768 (1)